866-997-4948(US-Canada Toll Free)

Waldenstrom Macroglobulinemia - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Apr 2014

Category :

Oncology

No. of Pages : 133 Pages

Waldenstrom Macroglobulinemia Pipeline Review, H1 2014, provides an overview of the Waldenstrom Macroglobulinemias therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Waldenstrom Macroglobulinemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Waldenstrom Macroglobulinemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Waldenstrom Macroglobulinemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Waldenstrom Macroglobulinemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Waldenstrom Macroglobulinemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Waldenstrom Macroglobulinemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
nstrom Macroglobulinemia - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 34
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
ibrutinib - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
carfilzomib - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
oprozomib - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
everolimus - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
idelalisib - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ofatumumab - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
GS-9973 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
IMO-8400 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
pevonedistat hydrochloride - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
MLN-0128 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
scFV-Chemokine DNA Vaccine - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
CC-292 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
venetoclax - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
KPT-330 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
INCB-040093 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
IST-1097 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
FV-162 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
FV-214 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Waldenstrom Macroglobulinemia - Recent Pipeline Updates 79
Waldenstrom Macroglobulinemia - Dormant Projects 121
Waldenstrom Macroglobulinemia - Discontinued Products 122
Waldenstrom Macroglobulinemia - Product Development Milestones 123
Featured News & Press Releases 123
Dec 04, 2013: Idera Pharmaceuticals Opens Enrollment for Phase 1/2 Clinical Trial of IMO-8400 in Waldenstr

List of Table

Table of Content

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Waldenstrom Macroglobulinemia Overview 8
Therapeutics Development 9
Pipeline Products for Waldenstrom Macroglobulinemia - Overview 9
Pipeline Products for Waldenstrom Macroglobulinemia - Comparative Analysis 10
Waldenstrom Macroglobulinemia - Therapeutics under Development by Companies 11
Waldenstrom Macroglobulinemia - Therapeutics under Investigation by Universities/Institutes 13
Waldenstrom Macroglobulinemia - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Waldenstrom Macroglobulinemia - Products under Development by Companies 16
Waldenstrom Macroglobulinemia - Products under Investigation by Universities/Institutes 17
Waldenstrom Macroglobulinemia - Companies Involved in Therapeutics Development 18
Gilead Sciences, Inc. 18
Millennium Pharmaceuticals, Inc. 19
Novartis AG 20
Genmab A/S 21
Celgene Corporation 22
Onyx Pharmaceuticals, Inc. 23
Incyte Corporation 24
Idera Pharmaceuticals, Inc. 25
Pharmacyclics, Inc. 26
Immune System Therapeutics Ltd. 27
Karyopharm Therapeutics, Inc. 28
AbbVie Inc. 29
Waldenstrom Macroglobulinemia - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 34
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
ibrutinib - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
carfilzomib - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
oprozomib - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
everolimus - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
idelalisib - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ofatumumab - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
GS-9973 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
IMO-8400 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
pevonedistat hydrochloride - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
MLN-0128 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
scFV-Chemokine DNA Vaccine - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
CC-292 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
venetoclax - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
KPT-330 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
INCB-040093 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
IST-1097 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
FV-162 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
FV-214 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Waldenstrom Macroglobulinemia - Recent Pipeline Updates 79
Waldenstrom Macroglobulinemia - Dormant Projects 121
Waldenstrom Macroglobulinemia - Discontinued Products 122
Waldenstrom Macroglobulinemia - Product Development Milestones 123
Featured News & Press Releases 123
Dec 04, 2013: Idera Pharmaceuticals Opens Enrollment for Phase 1/2 Clinical Trial of IMO-8400 in Waldenström’s Macroglobulinemia 123
Nov 07, 2013: Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations On Oprozomib at 55th American Society of Hematology Annual Meeting 123
Jun 20, 2013: Pharmacyclics Presents Ibrutinib Monotherapy Clinical Trial Data In Patients With Waldenstrom\'s Macroglobulinemia At ICML 124
Apr 01, 2013: Onyx Pharma To Present Data On Oprozomib At 14th International Myeloma Workshop 125
Feb 12, 2013: Janssen Announces FDA Grants Two Oncology Breakthrough Therapy Designations For Ibrutinib 126
Dec 06, 2012: TG Therapeutics To Present Clinical Data On Ublituximab At 54th American Society Of Hematology Meeting 126
Nov 06, 2012: Onyx Pharma Announces Data Presentations On Oprozomib At 54th American Society Of Hematology Annual Meeting 127
Nov 08, 2011: Genmab To Present Data On Ofatumumab At 53rd American Society Of Hematology Annual Meeting And Exposition 127
Nov 07, 2011: Pharmacyclics Reports Multiple PCI-32765 Presentations At 53rd American Society Of Hematology Annual Meeting 128
Jun 29, 2007: Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on Krx-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom\'s Macroglobulinemia 130

Appendix 132
Methodology 132
Coverage 132
Secondary Research 132
Primary Research 132
Expert Panel Validation 132
Contact Us 133
Disclaimer 133

List of Chart


Number of Products under Development for Waldenstrom Macroglobulinemia, H1 2014 9
Number of Products under Development for Waldenstrom Macroglobulinemia - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 14
Assessment by Monotherapy Products, H1 2014 30
Number of Products by Top 10 Target, H1 2014 31
Number of Products by Stage and Top 10 Target, H1 2014 32
Number of Products by Top 10 Mechanism of Action, H1 2014 34
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 35
Number of Products by Top 10 Route of Administration, H1 2014 37
Number of Products by Stage and Top 10 Route of Administration, H1 2014 38
Number of Products by Top 10 Molecule Type, H1 2014 39
Number of Products by Stage and Top 10 Molecule Type, H1 2014 40

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *